Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal
Biogen Inc. (NASDAQ:BIIB) and Stoke Therapeutics, Inc. (NASDAQ:STOK) collaborated to develop and commercialize zorevunersen ...
Leqembi® sales reaches €200 million - first sales milestone achieved
This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of ...
BioArctic: Leqembi sales reaches €200 million - first sales milestone achieved
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement ...
MM&M10h
Celebrities share uplifting messages for Alzheimer’s Association campaign
New treatments can slow the disease’s progress, which is why the Alzheimer’s Association is leveraging its celebrity partners ...
Biogen and Stoke Therapeutics collaborates to develop Dravet syndrome treatment globally
Biogen ( NASDAQ: BIIB) and Stoke Therapeutics ( NASDAQ: STOK) said on Tuesday they are collaborating to develop and ...